Related Experiment Video
Updated: Jun 6, 2026

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
Arsenic trioxide induces apoptosis in uveal melanoma cells through the mitochondrial pathway
Miao-Ju Chen1, Pei-Yu Yang, Yi-Zhen Ye
1Department of Medical Research, Show Chwan Memorial Hospital, Changhua, Taiwan.
Abstract:
Uveal melanoma, the most common primary intraocular malignancy in adults, is highly resistant to most chemotherapeutic drugs. Arsenic trioxide (ATO) is known to inhibit ocular melanoma cell growth. However, the effects of ATO on human uveal melanoma cells are poorly understood. Therefore, this study evaluated the mechanisms of ATO and its inhibiting effects on a human uveal melanoma cell line (SP6.5). An MTT assay indicated that, compared to human fibroblasts, ATO had a stronger inhibiting effect on SP6.5 cell proliferation in a dose- and time-dependent manner. The apoptosis ratio in SP6.5 cells, which was indicated by cell DNA fragmentation, was 4.1- to 7.7-fold higher after ATO-treatment. The ATO treatment substantially increased the activities of caspase-3 and caspase-9, but not of caspase-8. These findings were consistent with the protein expression observed by Western blots. ATO also significantly enhanced expression of Bax and cytochrome c proteins but suppressed those of Bcl-2. Therefore, ATO-induced apoptosis in uveal melanoma cells occurs mainly through the mitochondrial pathway rather than through the death receptor pathway. This report is the first to evaluate the complete mitochondria-dependent apoptotic pathway of ATO in uveal melanoma cells. These results can be used to improve the clinical effectiveness of ATO treatment for uveal melanoma.
Insights
Arsenic trioxide (ATO) effectively inhibits human uveal melanoma cell growth by inducing apoptosis. This occurs primarily through the mitochondria-dependent pathway, offering potential for improved clinical treatments.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Uveal melanoma is the most common primary intraocular malignancy in adults.
- It exhibits high resistance to conventional chemotherapeutic agents.
- Arsenic trioxide (ATO) shows promise in inhibiting ocular melanoma cell growth, but its mechanisms are not fully understood.
Purpose of the Study:
- To investigate the mechanisms of arsenic trioxide (ATO) in inhibiting human uveal melanoma cells.
- To evaluate the dose- and time-dependent effects of ATO on uveal melanoma cell proliferation.
- To elucidate the specific apoptotic pathway induced by ATO in uveal melanoma.
Main Methods:
- MTT assay to assess cell proliferation and viability.
- Measurement of apoptosis ratio via DNA fragmentation.
- Analysis of caspase activities (caspase-3, -9, and -8).
- Western blot analysis for key apoptosis-related proteins (Bax, Bcl-2, cytochrome c).
Main Results:
- ATO demonstrated a stronger inhibiting effect on uveal melanoma (SP6.5) cell proliferation compared to human fibroblasts.
- ATO treatment significantly increased the apoptosis ratio in SP6.5 cells (4.1- to 7.7-fold).
- ATO elevated caspase-3 and caspase-9 activities, enhanced Bax and cytochrome c expression, and suppressed Bcl-2 expression.
Conclusions:
- Arsenic trioxide (ATO) induces apoptosis in human uveal melanoma cells primarily through the mitochondrial pathway.
- The study provides the first comprehensive evaluation of the mitochondria-dependent apoptotic pathway of ATO in uveal melanoma.
- These findings suggest potential for enhancing the clinical efficacy of ATO for uveal melanoma treatment.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Apoptosis
The Extrinsic Apoptotic Pathway